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Abstract
Background: In 2010, researchers using novel laboratory techniques found that US-licensed rotavirus vaccines
contain DNA or DNA fragments from Porcine circovirus (PCV), a virus common among pigs but not believed to
cause illness in humans. We sought to understand pediatricians’ and mothers’ perspectives on this finding.
Methods: We conducted three iterations of focus groups for pediatricians and non-vaccine hesitant mothers in
Seattle, WA, Cincinnati, OH, and Rochester, NY. Focus groups explored perceptions of rotavirus disease, rotavirus
vaccination, and attitudes about the detection of PCV material in rotavirus vaccines.
Results: Pediatricians understood firsthand the success of rotavirus vaccines in preventing severe acute
gastroenteritis among infants and young children. They measured this benefit against the theoretical risk of DNA
material from PCV in rotavirus vaccines, determining overall that the PCV finding was of no clinical significance.
Particularly influential was the realization that the large, randomized clinical trials that found both vaccines to be
highly effective and safe were conducted with DNA material from PCV already in the vaccines.
Most mothers supported the ideal of full disclosure regarding vaccination risks and benefits. However, with a
scientific topic of this complexity, simplified information regarding PCV material in rotavirus vaccines seemed
frightening and suspicious, and detailed information was frequently overwhelming. Mothers often remarked that if
they did not understand a medical or technical topic regarding their child’s health, they relied on their
pediatrician’s guidance.
Many mothers and pediatricians were also concerned that persons who abstain from pork consumption for
religious or personal reasons may have unsubstantiated fears of the PCV finding.
Conclusions: Pediatricians considered the detection of DNA material from PCV in rotavirus vaccines a “non-issue”
and reported little hesitation in continuing to recommend the vaccines. Mothers desired transparency, but
ultimately trusted their pediatrician’s recommendation. Both vaccines are currently approved for their intended use,
and no risk of human PCV illness has been reported. Communicating this topic to pediatricians and mothers
requires sensitivity to a broad range of technical understanding and personal concerns.
Keywords: rotavirus vaccine, RotaTeq™?™?, Rotarix
®?®?, porcine circovirus (PCV), adventitious virus, pediatricians,
communication development, focus groups
* Correspondence: dvp6@cdc.gov
1Epidemiology Branch, Division of Viral Diseases, National Center for
Immunization and Respiratory Diseases, Centers for Disease Control and
Prevention, Atlanta, Georgia, USA
Full list of author information is available at the end of the article
Payne et al. BMC Pediatrics 2011, 11:83
http://www.biomedcentral.com/1471-2431/11/83
© 2011 Payne et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Rotavirus vaccines are oral, live, attenuated vaccines that
have been shown in large clinical trials and through
post-licensure surveillance to be safe and highly effective
in protecting children against severe rotavirus gastroen-
teritis [1-8]. During the course of testing novel virus-
detection techniques, Victoria et al. [9] unexpectedly
identified nucleic acids from one adventitious virus in
Rotarix
®, the licensed, monovalent rotavirus vaccine
produced by GlaxoSmithKline Biologicals (Rixensart,
Belgium). The detected virus shared 98% identity to Por-
cine circovirus (PCV) -1, and covered the complete cir-
cular genome. PCV is a virus that commonly infects
pigs and has been detected in 5% of stool samples from
US adults, likely as a result of dietary consumption of
pork products [9], but PCV is not believed to cause ill-
ness among humans [9-11].
In early 2010, this finding was reported to the US
Food and Drug Administration (FDA). On March 22,
2010, FDA released a recommendation for clinicians to
temporarily suspend use of Rotarix
®, although there
was no evidence of a safety risk. On May 6, 2010, FDA
reported preliminary findings that RotaTeq™,t h e
licensed, pentavalent rotavirus vaccine produced by
Merck and Co. (Whitehouse Station, NJ), also contains
detectable PCV (-1a n d- 2 ) material. On May 7, 2010,
the FDA Vaccines and Related Biological Products
Advisory Committee (VRBPAC) convened. On the
basis of available evidence regarding a theoretical risk
of PCV infection among humans and the observed
benefits of rotavirus vaccines in preventing severe
acute gastroenteritis among infants, VRBPAC panelists
expressed reassurance that the detection of DNA and
DNA fragments from PCV in rotavirus vaccines was
not likely to cause harm to humans and recommended
that information on this topic be provided prior to
vaccination.
On May 14, 2010, FDA issued a recommendation for
clinicians to resume use of Rotarix
® and to continue use
of RotaTeq™. Subsequent investigation suggests that
PCV material was introduced into both rotavirus vac-
cines through porcine-derived trypsin–a reagent used in
the cell-culture growth process of vaccine production–
commencing several years before randomized, con-
trolled, multi-center phase III clinical vaccine trials were
conducted for both vaccines [12,13].
Previous findings of adventitious viruses in live, atte-
nuated vaccines have been relatively rare and followed
by studies determining the agents to not be associated
with human illness [14-16]. These instances have often
arisen through inadvertent introductions of adventitious
viruses or viral materials during vaccine production,
often via incomplete inactivation during the attenuation
process.
In June 2010, the US Centers for Disease Control and
Prevention (CDC) partnered with three existing rota-
virus surveillance sites to conduct focus groups of pedia-
tricians and mothers to assess their perspectives and the
communications issues regarding rotavirus vaccines and
PCV. An assessment to measure whether focus group
participants changed their attitudes regarding rotavirus
vaccines also followed the focus group discussions.
Methods
Interview Procedures
We conducted three iterations of focus groups for
pediatricians and mothers in Seattle, WA; Cincinnati,
OH; and Rochester, NY (total of 9 physician and 9 par-
ent focus groups). A standard protocol, moderator
guides, and pre-/post- test comparisons of acceptability
of the rotavirus vaccine were uniformly applied.
The initial focus groups were held in July 2010,
approximately 4 months following the first public
announcement of PCV in a rotavirus vaccine, and
approximately 2 months following the FDA recommen-
dation to resume/continue rotavirus vaccinations. Two
further focus group iterations occurred in August and
September 2010. All focus group iterations included
core discussions on rotavirus disease and rotavirus vac-
cines, followed by information on PCV. Co-investigators
developed communication materials and messages prior
to the focus group sessions and obtained parent and
pediatrician feedback on these materials during the
focus group discussions. The moderator’sg u i d ea n d
communication materials were then revised iteratively
based upon comments and data obtained from the pre-
vious focus groups until conceptual insights were
exhausted. The focus groups lasted approximately 90
minutes. Although each moderator was independent
and experienced in leading focus groups, participant
responses may be affected by the manner in which
information is conveyed to the focus groups.
Study Population
Each focus group consisted of up to 8 unique partici-
pants. Physician participation was restricted to actively
practicing, board-certified/-eligible, non-military, pri-
mary care pediatricians who typically administered >4
rotavirus vaccine doses per week. In each focus group,
only one pediatrician participated from any given office.
Participants were excluded if the pediatrician or his/her
immediate family member worked in vaccine develop-
ment, marketing, research, or regulation. Recruitment of
pediatricians occurred through community pediatrician
list serves, at events (e.g., grand rounds), and other
administrative meetings, and the study team followed up
with interested participants for a determination of
eligibility.
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Page 2 of 11Mothers at least18 years of age who reported having
normally developing children between 6 months and 4
years of age were eligible for participation if they 1)
were fluent and literate in English, 2) agreed to routine
vaccination for the index child, and 3) at least partially
influenced health-care decisions for their child. The
ineligibility of mothers with an infant <6 months of age
was intended to avoid the focus group discussions from
influencing a mother’s decision to have a current infant
vaccinated or not. Potential participants were excluded
if they or any immediate family member worked in vac-
cine development, marketing, research, or regulation; if
they participated in any market study within the pre-
vious 6 months; or if they worked in the healthcare
field. For each focus group, recruiters attempted to
enroll at least 2 mothers with the educational attain-
ment of a high school diploma or less. While these elig-
ibility and exclusionary criteria for mothers were
consistently applied across participating sites, the sam-
pling frame and solicitation methods for mothers dif-
fered by site. In Seattle, mothers were recruited from a
university-based primary care clinic, but in Cincinnati
and Rochester a marketing telephone list was used to
contact households for eligibility.
Interview Guide
Focus group questions were open-ended, non-sensitive,
and designed to maintain participant privacy. They
included the following domains: a) perceptions of rota-
virus disease, b) perceptions of rotavirus vaccination, c)
attitudes toward the detection of PCV material in rota-
virus vaccines, and, d) attitudes toward communication
materials on these topics.
Qualitative Data Analysis and Presentation
After each round of focus groups at each site, the audio-
taped discussions were transcribed verbatim and then
analyzed by use of an inductive coding technique for
qualitative data [17,18]. Each investigator independently
read each focus group transcripts specific to their site(s)
and abstracted key themes regarding rotavirus disease,
rotavirus vaccine, attitudes regarding the PCV finding,
and communications. Investigators then met to discuss
their independent analyses and negotiate a final list of
themes. Quotations used in this article were excerpted
from transcripts and are representative of the category
to which they have been assigned. Group dynamics
inherently affect focus group results and this was taken
into consideration during our analysis.
Comparison of Participants’ Pre- and Post-Focus Group
Questionnaires
We asked attitudinal questions at the beginning and end
of each focus group to compare whether or not the
focus group discussion had influenced or changed sub-
ject perceptions of rotavirus vaccines. These questions
included attitudes and opinions regarding rotavirus vac-
cination (i.e., their acceptability, understanding and bar-
riers to rotavirus vaccination). Changes in pre- and
post-focus group questionnaire responses were assessed
using the Wilcoxon signed rank test for non-normal dis-
tributions. For these comparisons, the estimated aggre-
gated study power was >90% for pediatricians and
mothers.
Ethics
Prior to focus group enrollment, the CDC Human
Research Protection Office determined this evaluation to
constitute a public health non-research project, and the
institutional review boards at each participating institu-
tion (Seattle Children’s Hospital, University of Roche-
ster, New York, School of Medicine and Dentistry,
Cincinnati Children’s Hospital and Medical Center)
declared the project to be exempt. Potential participants
consented to participate at screening and if they decided
not to participate, they were thanked for their time and
not contacted further. Permission to audiotape was
obtained during screening and again at the outset of the
group.
Results
Focus groups commenced approximately 4 months fol-
lowing the first public announcement of PCV in a
rotavirus vaccine and approximately 2 months follow-
ing the FDA recommendation to resume/continue
rotavirus vaccinations. Results are presented in order
of characteristics of the subjects, major respondent
themes (pediatrician, parent, overarching), communica-
tion recommendations, and results of the pre-/post-
focus group comparison of attitudes and opinions
regarding rotavirus vaccines.
Participant Characteristics
We conducted focus groups in three different regions of
the United States (the West, Midwest, and Northeast).
Table 1 describes the characteristics of pediatricians (n
= 45) (Table 1) and mothers (n = 58) (Table 2) partici-
pating in focus groups. Pediatricians had an average
15.4 years of experience (median = 15, range = 1-39)
following residency, and most (62%) belonged to a pri-
vate practice group. About one-third of the children
enrolled by their pediatric offices were publicly insured
and eligible for the Vaccines for Children Program, [19]
a federally-funded entitlement program providing vac-
cines at no cost to socioeconomically disadvantaged
children. Most pediatricians solely administered Rota-
Teq™ (76%), compared with 4% who solely used
Rotarix
® and 20% who reported using both vaccines.
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strongly or somewhat agreed to the statement, “Before
rotavirus vaccine was available, rotavirus was the most
common cause of severe infectious diarrhea in children
<2 years old in the US.” About three-quarters (76%)
strongly or somewhat agreed that rotavirus was respon-
sible for more annual hospitalizations than influenza
during the pre-vaccine era.
The average age for participating mothers was 33.2
years (median = 33.5, range = 21-44), and 76% had
achieved more than a high school education. Most
mothers (61%) reported being privately insured, com-
pared with 33% having public insurance/Medicaid.
The average household had 2.3 children, and most
mothers (79%) had heard of rotavirus before the focus
group.
Pediatrician Themes
Many pediatricians had negative memories of rotavirus
infections and had observed a high burden of childhood
Table 1 Characteristics of pediatricians participating in focus groups by site
Pediatrician Characteristics Seattle
(N =
12)
Rochester
(N = 16)
Cincinnati
(N = 17)
Total
(N = 45)
Average number of years since residency (years) 10.2 15.6 18.0 15.4
range (1-39)
Description of practice
Solo 04 0 4
Private group 8 9 11 28
Non-profit community 1 0 4 5
Medical school-based practice 2 1 2 5
Hospital-based practice 1 1 0 2
Other 01 0 1
Average number of full-time physicians in practice 23.7 3.9 7.9 10.7
range (1-75)
Location of practice
Urban 94 7 2 0
Suburban 31 1 1 0 2 4
Average number of newborns (<1 month old) enrolled in practice last month 77.9 22.3 39.7 43.7
range (3-300)
Average percentage of children with public insurance/Medicaid in practice 27% 27% 40% 32%
Average percentage of children eligible for Vaccines For Children (VFC) in practice 35% 31% 41% 36%
Which rotavirus vaccine do you use?
RotaTeq™ 12 12 10 34
Rotarix
® 01 1 2
Both 03 6 9
Neither 00 0 0
Before rotavirus vaccine was available, rotavirus was the most common cause of severe
infectious diarrhea in children <2 years old in the U.S.
(% agreed)
Strongly agree (1) 5 9 12 26
Somewhat agree (2) 43 4 1 1
Somewhat disagree (3) 2 1 1 4
Strongly disagree (4) 13 0 4
Average score 1.9 1.9 1.4 1.7
Before rotavirus vaccine was available, rotavirus was responsible for more hospitalizations
annually than influenza.
(% agreed)
Strongly agree (1) 26 6 1 4
Somewhat agree (2) 5 5 10 20
Somewhat disagree (3) 5 4 1 10
Strongly disagree (4) 01 0 1
Average score 2.3 2.0 1.7 2.0
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Page 4 of 11disease from rotavirus gastroenteritis, as represented by
common remarks included in Table 3. Those pediatri-
cians who had the opportunity to observe rotavirus both
during and after the pre-vaccine era understood first-
hand the success of rotavirus vaccines in preventing
severe pediatric acute gastroenteritis (Table 4).
Overall, pediatricians reported that the mothers of
their patients rarely hesitated to accept rotavirus vacci-
nation. Specifically noted were reports that, “[Mothers]
are willing to accept [rotavirus vaccine] when you say
the virus gives horrible vomiting and diarrhea and it can
last two weeks.” As the vaccines are orally administered,
pediatrician participants stated that many mothers do
not count it among the injections recommended in the
vaccination schedule.
At the time of the focus groups, most participating
pediatricians had some prior knowledge that DNA
material from PCV had been detected in rotavirus vac-
cines. When given detailed information on this topic,
many seemed to intuitively measure the theoretical risks
of PCV against the benefits they personally observed
from rotavirus vaccination. Nearly every participating
pediatrician expressed an opinion that the detection of
DNA or DNA fragments from PCV in rotavirus vaccines
was not clinically important, repeatedly using the term
“non-issue.” Particularly influential to this appraisal was
that the published, large phase III randomized clinical
trials that found both vaccines to be highly effective and
safe were actually conducted with DNA material from
PCV already in both vaccines. Respondents reported
that, “Now I’ve learned that the particles have been there
from day one, so if you believe the safety data on the
vaccine itself then you believe that [the vaccine] is safe.”
Furthermore, many pediatricians found reassuring that
Table 2 Characteristics of mothers participating in focus groups by site
Parental Characteristics Seattle
(N = 13)
Rochester
(N = 18)
Cincinnati
(N = 27)
Total
(N = 58)
Average maternal age (years) 34.5 31.3 32.9 33.2
range (21-44)
Level of maternal education
Less than high school 1 2 0 3
High school 2 4 5 11
Some college 1 6 10 17
College 2 5 9 16
Post-college graduate degree 7 1 3 11
Location of household
Urban 10 8 2 20
Suburban 1 10 22 33
Rural 1 0 3 4
Insurance status
Public insurance/Medicaid 4 11 4 19
Private 8 7 20 35
Uninsured 0 0 1 1
Other 0 0 2 2
Average number of children in household 2.5 2.3 2.2 2.3
Have heard of rotavirus vaccine before (%) 83% 56% 93% 79%
Table 3 Examples of common comments from pediatricians regarding rotavirus disease
“We have lots of experience with rotavirus disease. I think vomiting and diarrhea ranks up there with my least favorite illness, because it’s a lot of
supportive care, a lot of phone calls, a lot of coming back to the office, a lot of reevaluation, and there’s nothing you can do other than fluids.”
“Most kids did okay on oral rehydration, but we had a lot who were hospitalized for IV therapy.”
“I went through residency in the late ‘80 s, and we used to have an entire ward that would be filled with kids with really horrible diarrhea. Entire
wards that would fill up the hospital, to the point that people would say, ‘You don’t want to be on [the infant floor] during rotaviral season.’
Because ...you would get 25, 30 admissions a night and most of them would be having diarrhea and a lot of them would be almost in shock
because of it. You could see how in a place where there weren’t resources for IV fluids that there would be a lot of deaths from dehydration.”
“I remember how contagious it is, and how it lives on surfaces and we’d have to gown, glove, mask, and practically use dedicated equipment for
the rooms in hospital. And if you suspected it in the outpatient setting, you had to be extremely careful by cleaning the room down. It just spread
within families, but the babies would be the sickest.”
“Over the years, we’ve had some significantly ill kids from [rotavirus]. One kid had a shock-like response to rotavirus and it totally devastated him, so
that he’s probably one of the sickest little developmentally devastated kids in the practice and it was from rotavirus years ago.”
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“... [humans are] literally exposed to thousands of viruses
every day and don’tb e c o m ei l l . ” Since PCV material is
likely consumed by many people in pork products with-
out adverse consequences, many observed that, “...we
are exposed to [PCV] in the pork we eat, and we’re fine.
So this is not our only exposure. It’sn o tan e wv i r u st o
us.”
Given their general dismissal of any theoretical risk
from DNA material from PCV in rotavirus vaccines,
many pediatricians indicated that they would not devote
time to explain the PCV finding, although many agreed
that they would provide information to mothers who
specifically queried them on the topic. Their general
reluctance was rooted in three stated reasons: 1) DNA
material from PCV in rotavirus vaccines did not consti-
tute any risk, so the point was both moot and unduly
alarming to the mothers, 2) discussion would be lengthy
(and potentially non-reimbursable) and would compete
with discussion of many other important clinically rele-
v a n tt o p i c s ,a n d ,3 )m a n ym o t h e r sw o u l dn o tf u l l y
understand the issue even with further elaboration.
Maternal Themes
While more than three-quarters of the participating
mothers had at least some college education, many
expressed a general lack of scientific and technical
understanding of viruses, DNA, how vaccines are manu-
factured, and how vaccines work. Approximately one-
fifth (21%) of the mothers reported unfamiliarity with
the disease “rotavirus” and nearly none had prior knowl-
edge of the PCV finding. One mother remarked, “I guess
what all of this brings up for me is that I don’tr e a l l y
understand what’si nv a c c i n e s . . .i tm a k e sm ef e e ll i k eI
want to understand more what a vaccine actually is,
that this is what’s happening... that there’s a virus that
somehow got in there that people didn’tk n o wa b o u t . ”
Simplified information regarding PCV material in rota-
virus vaccines seemed frightening, while detailed infor-
mation was frequently overwhelming. “Id o n ’tk n o w
what the porcine circovirus is, so to me, this statement
sounds like there’s another virus present in the rotavirus
vaccine. So, that would concern me.” Stating that the
vaccine was simply “safe” without providing evidence
often brought further suspicion, exemplified by the com-
ment, “When they say something is safe... well, it’s the
classic hedge. They don’t have any evidence that it’sn o t
safe, which just means that they may not have studied it
enough.”
Mothers largely supported the ideal of transparency in
being provided information regarding all vaccine risks
and benefits. However, mothers often remarked that if
they did not understand a medical or technical topic
regarding their children’s health they commonly relied
on their pediatrician’s guidance. Nonetheless, a few
mothers mentioned that the detection of PCV material
in rotavirus vaccines eroded their confidence in the vac-
cines (Table 5).
Overarching Themes
Many mothers and pediatricians expressed alarm that
those who abstain from pork consumption for religious
or personal reasons may have unsubstantiated fears that
PCV is pig material (rather than the fact that PCV is a
virus commonly found in pigs). Concern was most
directed at whether parents of Jewish or Muslim faiths
would reject the vaccines due to this misunderstanding.
Some participants were similarly concerned that, due to
its name, Porcine circovirus was somehow related to
H1N1 influenza (a.k.a. swine flu) or illnesses of animal
origin (e.g., bovine spongiform encephalopathy, a.k.a.
mad cow disease) (Table 6).
Pediatricians and some mothers cautioned that using
the same acronym, PCV, for both Porcine circovirus and
pneumococcal conjugate vaccine could cause confusion.
Communication Recommendations
Vaccine Information Sheet (VIS) recommendations
Focus group participants indicated that a general state-
ment should not replace further discussion between
pediatrician and mother regarding the PCV finding.
However, on the basis of themes elicited from focus
group participants, the following paragraph was devel-
oped for the rotavirus vaccine information sheet (VIS)
that is provided to all vaccinees:
“A virus (or parts of a virus) called porcine circovirus
(PCV) is present in both rotavirus vaccines. There is no
evidence that PCV is a safety risk or causes illness in
humans, and these rotavirus vaccines have been shown
to be safe and effective at preventing severe diarrhea. If
you have questions, ask your doctor or visit http://www.
cdc.gov/vaccines/vpd-vac/rotavirus.“
Table 4 Examples of comments from pediatricians regarding the post-licensure rotavirus vaccination period
“It’s been interesting to see over the years. [Before the vaccine was introduced] you would get kids coming in just bone dry, couldn’t find the vein
to start an IV... And to see that all change so much, it’s been really remarkable.”
“Well it’s definitely changed over time since the advent of the vaccine. It wasn’t that uncommon to have to send kids over [to be hospitalized] for
rehydration or to work through the severe diarrhea and the vomiting. [Now] it’s just not as common at all to have to refer for that.”
“...after [rotavirus vaccine] was introduced, it was nice to see the drastic change. ...maybe [hospitalizations for IV therapy] dropped by 90 percent.”
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ing VIS sheets for the first time during the office visit
was inopportune. Some mothers acknowledged that the
VIS was infrequently read at the health care visit, com-
monly stating, “By the time your kid actually gets the
shot, you’ve waited in the waiting room, you’ve waited in
the greeting room. You might have one, two, or three
more older kids with you. They’re all melting down, and
of course, when they get their shots, then that’s just horri-
ble for everybody. So, how much of this [VIS] you might
actually read right there, when you need to know it
before you make a decision... not going to happen.”
Instead, being given this information in advance of the
visit could provide mothers an opportunity to discuss
the information with other caregivers and to research
any concerns in advance of vaccination. Pediatricians
generally remarked that they have limited time to dis-
cuss the vaccines or vaccine concerns at a well-child
visit. Some pediatricians remarked that they proactively
give VIS sheets as early as during the routine neonatal
visits in order for parents to review future vaccinations
in advance.
General communication perspectives
Mothers most frequently trusted the recommendations
of their pediatricians. Pediatricians stated that they most
trusted statements and medical alerts coming from the
American Academy of Pediatrics (AAP).
Participants noted that websites of public health agen-
cies and medical organizations should reflect relevant
and updated information. Mothers emphasized that they
should be referred to a specific webpage address with
this information, not to a general agency or organiza-
tional home web address, to avoid difficulty in finding
the correct material.
Several pediatricians using electronic medical records
and automated information systems suggested that a
few statements on the PCV finding be proposed that
can be included in “dot phrase” information dissemina-
tion. “Dot phrases” are pieces of information that the
health care provider can select to include in persona-
lized information that can be provided during an office
visit.
Results of Pre-/Post-test
Following the focus group discussion of rotavirus, rota-
virus vaccines and PCV, pediatricians showed no statisti-
cally significant changes in their recommendation of
rotavirus vaccines or in perceived barriers to vaccina-
tion. Nearly all pediatricians (98%) reported no change
in their opinion to recommend the vaccines (P = 1.00).
Also, no appreciable net change was observed among
pediatricians who reported that parental concern with
vaccine safety would be a barrier to rotavirus vaccina-
tion (26% reported vaccine safety to be an increased
barrier, whereas 23% reported it to be a diminished bar-
rier; P = 0.75). (Tables 7 and 8)
Mothers, however, had more negative perceptions
regarding the importance and safety of the vaccines and
whether a subsequent baby would receive rotavirus vac-
cines. Roughly half of the participating mothers contin-
ued to feel confident that rot a v i r u sv a c c i n e sa r es a f e ,
while 37% changed their opinion to disagree with this
Table 5 Examples of comments from mothers regarding PCV materials found in rotavirus vaccines
“I’d really like to see information [on PCV] if it was going in my child.”
“Clarification would be good as to how it got there, or what purpose it serves in the vaccine. I think that would be a good thing to know.”
“If my doctor is going to recommend it, more than likely, I’m just going to go with it. If they feel it’s necessary, I trust them.”
“I’m probably putting too much trust in my pediatrician, but I feel like he’s going to tell me everything important that I need to know beforehand.”
“You know, I have my 2 children and can talk about what’s happened with them but, the doctor sees 20, 30, 40 kids a day so there’s a lot more
exposure to kids who’ve had the rotavirus vaccine and what happens, and what happens when they don’t [get the vaccine].”
“I’m sure with all the new technology, you’re going to find all kinds of things in vaccines, and as long as they’re safe, I mean, if the doctor is going
to recommend it, or the CDC, I think that’s good enough.”
“I still feel like the benefits outweigh the risks but every time I [hear] something like this, I feel a little bit less confident.”
Table 6 Examples of comments from pediatricians representing fears and concerns regarding PCV materials in
rotavirus vaccines
“I assume you’ll have people asking if it’s related to swine flu if you write the name out like that. Doesn’t ‘porcine’ mean, ‘related to pigs’?
Everybody’s obsessed with swine flu right now, so that always worries people.”
“...there are a lot of things that start within the animal population that transfer over to humans and can be far more devastating.”
“Then I started thinking about the ‘what-ifs’ that [my patients’ parents] will be asking; ‘Well about that avian thing, the avian flu? It never caused a
problem in anybody else, but then it found a way to combine with a human type virus.”
“A lot of my [patients’] parents don’t eat pork. They’re very naturalist [sic]. They’re going to see pork, and then they’ll see virus. And they’re going to
stop there, and they’re going to say I don’t want my child to get this vaccine. They’ll assume there’s another virus in it, and they’ll think of swine flu,
pork, and then it just becomes this whole association that they’ll go crazy with.”
Payne et al. BMC Pediatrics 2011, 11:83
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sion, 16 of 52 mothers somewhat or strongly disagreed
with the statement “If I had another baby, I would have
that baby get rotavirus vaccine.”, compared with 4 of 52
mothers stating this during the pre-focus group ques-
tionnaire. This indicates that 12 (23%) of 52 participat-
ing mothers changed their opinion on this issue
following the focus group discussion. (P < 0.01) No sig-
nificant change was observed regarding parental confi-
dence that rotavirus vaccine prevents severe diarrhea
(Tables 7 and 8).
Discussion
Stating that there was no evidence that DNA or DNA
fragments from PCV in rotavirus vaccines would cause
harm to humans, FDA issued a recommendation for
health care workers to resume administering Rotarix
®
and to continue administering RotaTeq™.A tt h a tt i m e ,
little understanding existed for how best to
communicate this complicated finding. Since the incep-
tion of our qualitative study, FDA has announced that it
is investigating additional testing and technologies to be
implemented into the vaccine production process to
prevent adventitious agents from being introduced to
vaccines [20]. Additionally, both rotavirus vaccine man-
ufacturers have changed their vaccines’ labels to notify
consumers of the PCV findings [21,22] (Table 9).
Human risk of PCV illness has not been detected in
clinical assessments [12,13], but subsequent laboratory
analyses of Rotarix
® have detected the presence of infec-
tious PCV-1 in a cell culture assay, and the presence of
PCV-1 and PCV-2 DNA in RotaTeq™ which tested
negative for growth in cell culture assays [23].
Our results demonstrate that pediatricians measured
the observed benefit of rotavirus vaccines against the
detection of DNA material from PCV in rotavirus vac-
cines and concluded, overall, that this finding was not
clinically significant. Nearly every pediatrician
Table 7 Pre-focus group assessment results: Pediatricians and Mothers
Initial Pediatrician Perceptions
What are your current
recommendations on
rotavirus vaccinations for
infants?
Perceived Barrier
-
Lack of insurance coverage
Perceived Barrier
-
Lack of
reimbursement
Perceived Barrier
-
Mother’s concern with
vaccine safety
Perceived
Barrier
-
Time needed
to discuss
with mothers
Routinely
recommend
(1)
44 (98%) 3 (7%) 1 (2%) 6 (14%) 0 (0%)
Occasionally
recommend
(2)
0 (0%) 2 (4%) 5 (11%) 23 (53%) 2 (4%)
Inform but
don’t
recommend
(3)
0 (0%) 15 (33%) 12 (27%) 8 (18%) 23 (51%)
Recommend
against (4)
1 (2%) 25 (56%) 27 (60%) 7 (16%) 20 (44%)
Average
score
1.1 3.4 3.4 2.4 3.4
Initial Maternal Perceptions
Rotavirus vaccine is an
important vaccine for my
child
I feel confident that
rotavirus vaccine works to
prevent serious diarrhea
I feel confident
that rotavirus
vaccine is safe
If I had another baby, I
would have that baby get
rotavirus vaccine
Strongly
agree (1)
27 (53%) 20 (39%) 23 (45%) 37 (71%)
Somewhat
agree (2)
22 (43%) 30 (58%) 23 (45%) 11 (21%)
Somewhat
disagree (3)
2 (4%) 1 (2%) 5 (10%) 4 (8%)
Strongly
disagree (4)
0 (0%) 1 (2%) 0 (0%) 0 (0%)
Average
score
1.5 1.7 1.6 1.4
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routinely recommending rotavirus vaccines to infants.
Particularly influential to their appraisal was that the
large, randomized clinical trials that found both vaccines
to be highly effective and safe were conducted with
DNA or DNA fragments from PCV already in the
vaccines.
Mothers consistently supported the ideal of transpar-
ency and disclosure regarding all vaccination risks and
benefits. However, the desire for informational transpar-
ency was frequently incompatible with limitations in the
comprehension of core scientific and technical informa-
tion exhibited by many mothers. Through testing several
iterations of messages of varying sophistication and
depth, we found that even providing simplified messages
was often insufficient to prevent confusion over the
complicated underlying concepts. Short, simple state-
ments given to our focus group mothers on this topic
often seemed alarming and potentially motivated future
vaccine refusal, while providing more detailed informa-
tion was considered overwhelming and provoked suspi-
cion. However, as observed by the National
Immunization Survey, in which mothers who expressed
misconceptions regarding risks and benefits of vaccina-
tion were positively influenced towards vaccination
through the guidance of their health care provider, [24]
our results indicated that mothers commonly relied on
their pediatricians’ advice when confronted with a diffi-
cult medical or technical topic regarding their child’s
health.
In the end, building a maternal cognitive assessment
of benefits and theoretical risks regarding the detection
of DNA material from PCV in rotavirus vaccines is unli-
kely to be cultivated by simply providing an untailored
textual statement. A skillfully navigated, personalized
discussion between an interested mother and pediatri-
cian, employing sensitivity to a mother’s specific techni-
cal understanding and personal concerns on this topic,
Table 8 Comparison of Pre- and Post-focus group questionnaires: Pediatricians and Mothers
Change in Pediatrician Perceptions
What are your current
recommendations on
rotavirus vaccinations for
infants?
Important barrier -
Lack of insurance coverage
Important
barrier -
Lack of
reimbursement
Important barrier -
Mother’s concern
with vaccine safety
Important
barrier -
Time needed
to discuss
with mothers
More likely to
recommend
1 (2%) 11 (25%) 5 (12%) 11 (26%) 11 (24%)
Same answer 43 (98%) 25 (57%) 32 (76%) 22 (52%) 27 (60%)
Less likely to
recommend
0 (0%) 8 (18%) 5 (12%) 10 (23%) 7 (16%)
P-value Ж P = 1.00 P = 0.18 P = 1.00 P = 0.75 P = 0.18
Change in Maternal Perceptions
Rotavirus vaccine is an
important vaccine for my
child
I feel confident that
rotavirus vaccine works to
prevent serious diarrhea
I feel confident
that rotavirus
vaccine is safe
If I had another baby, I
would have that baby get
rotavirus vaccine
More likely to
agree with
statement
5 (10%) 10 (19%) 6 (12%) 1 (2%)
Same answer 32 (63%) 37 (71%) 26 (51%) 35 (67%)
More likely to
disagree
with
statement
14 (28%) 5 (10%) 19 (37%) 16 (31%)
P-value Ж P = 0.01 § P = 0.17 P < 0.01 § P < 0.01 §
Ж Wilcoxon signed rank sum test
§ indicates that the post-focus group response changed with statistical significance
Table 9 Label changes to Rotarix
® and RotaTeq™ vaccines (circa 2010)
Rotarix
® label “In the manufacturing process, porcine-derived materials are used.
Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans.”
RotaTeq™
label
“In the manufacturing process for RotaTeq, a porcine-derived material is used. DNA from porcine circoviruses (PCV) 1 and 2 has
been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans.”
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Page 9 of 11is likely the best option, although perhaps the most diffi-
cult one. One pediatrician offered the following sce-
nario, “I might ask the parents, ‘Is there anything specific
that you’re concerned about?’ and see if this comes up. If
they said, ‘I heard something about something in the
vaccine’, then I might say, ‘Well, yes, we’ve heard of that
as well, but we are not concerned.” Other pediatricians
indicated that they would gauge the mother’so w nl e v e l
of scientific understanding in discussing the topic, while
still others openly acknowledged that they would avoid
such a discussion altogether. If individualized informa-
tion is to be shared with the mother, this should ideally
occur well in advance of the vaccination event. Internet
and email communications from trusted sources, such
as AAP, appear effective in communicating this topic to
pediatricians.
In an analysis of HealthStyles survey data by Gust et
al. [25], mothers who disagreed that they had sufficient
information to make a decision on whether to vaccinate
a child also reported that they had less confidence in
the safety of childhood vaccines and had difficulty com-
municating with their health care provider. Furthermore,
as our data also indicate, Gust et al. suggested that a
health care provider simply communicating the risks
and benefits of vaccination works to build the underly-
ing confidence in the vaccines themselves. Other studies
have demonstrated that parents consistently cite their
child’s provider as an important and trusted influence in
their immunization decision-making [24,26-29].
There are several potential limitations to this study.
First, the focus group setting is an artificial environment
for receiving the concentrated information that was disse-
minated to our participants. This may have caused partici-
pants to respond with greater intensity and suspicion
regarding why the focus group was being held than they
normally would have on the basis of a cursory, quotidian
discussion. Our focus group participants may not be
representative of the larger population; thus, the themes
identified may not be generalizable. We focused upon
pediatrician and maternal perspectives for this assessment
but recognize the role of other health professionals in
communicating this information, and fathers/other care-
takers in health care decision-making. Last, as we con-
ducted the focus groups within a brief period following
the first publicly disseminated information regarding this
topic, it is unclear to what extent our focus group results
represent time-limited responses. Further investigation
could explore psychological and media theories to specu-
late upon the possible permanence of these findings.
Conclusions
We found that pediatricians did not perceive the finding
of DNA or DNA fragments from PCV in rotavirus vac-
cines to be of clinical importance and reported near-
unanimous confidence in continuing to administer rota-
virus vaccines. This finding did not match the percep-
tions of mothers who desired to but, in many cases, had
difficulty in independently assessing the potential risk-
benefit profile of the rotavirus vaccines. Fostering skill-
ful, personalized communication between pediatricians
and mothers appears paramount in understanding such
risk-benefit assessments regarding rotavirus vaccines.
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